Summary

Market Overview
The Global Beta blockers Market, valued at USD 9.94 Billion in 2024, is projected to experience a CAGR of 5.95% to reach USD 14.06 Billion by 2030. Beta blockers represent a class of pharmaceutical agents that function by inhibiting the effects of epinephrine, also known as adrenaline, on the heart and blood vessels. This action results in a reduced heart rate and decreased force of cardiac contraction, thereby lowering blood pressure and enhancing blood flow. The global market for beta blockers is primarily driven by the rising prevalence of cardiovascular diseases, including hypertension, angina, and arrhythmias, coupled with an expanding geriatric population that is inherently more susceptible to such conditions.
Key Market Drivers
The increasing burden of cardiovascular diseases represents a fundamental driver for the global beta blockers market. These conditions, encompassing hypertension, angina, and various arrhythmias, necessitate therapeutic interventions to manage symptoms and prevent disease progression. The continued rise in these diagnoses directly expands the patient pool requiring cardiac medications.
Key Market Challenges
The impact of patent expirations on key brand-name beta blockers poses a significant challenge to the growth of the global market. Upon the loss of patent exclusivity, generic manufacturers introduce bioequivalent versions, intensifying price competition and increasing market saturation. This dynamic typically results in a substantial decline in revenue for originator companies as market share shifts towards these lower-priced generic alternatives.
Key Market Trends
The global beta blockers market is significantly influenced by the continuous development of more sophisticated drug delivery systems and enhanced therapeutic profiles. This trend, encompassing both novel formulations and next-generation agents, aims to improve patient outcomes through optimized pharmacokinetics and reduced side effects. For instance, the United States Pharmacopeia announced on August 30, 2024, that four new dissolution tests were added to the Metoprolol Succinate Extended-Release Tablets monograph, reflecting ongoing FDA approvals of diverse extended-release formulations.
Key Market Players
• Pfizer Inc
• Novartis AG
• Merck & Co. Inc
• AstraZeneca PLC
• Johnson and Johnson Services, Inc.
• Eli Lilly and Company
• Sanofi SA
• Bristol-Myers Squibb
• Bayer AG
• GlaxoSmithKline plc
Report Scope:
In this report, the Global Beta blockers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Beta blockers Market, By Type:
o Non-selective Agents
o Selective Agents
• Beta blockers Market, By Indications:
o Angina Pectoris
o Heart Failure
o High Blood Pressure
o Others
• Beta blockers Market, By Drugs:
o Betaxolol
o Acebutolol
o Esmolol
o Others
• Beta blockers Market, By Distribution Channel:
o Hospital Pharmacy
o Retail Pharmacy
o Online Pharmacy
• Beta blockers Market, By Application:
o Cardiac Diseases
o Hypertension
o Glaucoma
o Others
• Beta blockers Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Beta blockers Market.
Available Customizations:
Global Beta blockers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Beta blockers Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Type (Non-selective Agents, Selective Agents)
5.2.2. By Indications (Angina Pectoris, Heart Failure, High Blood Pressure, Others)
5.2.3. By Drugs (Betaxolol, Acebutolol, Esmolol, Others)
5.2.4. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
5.2.5. By Application (Cardiac Diseases, Hypertension, Glaucoma, Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. North America Beta blockers Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Type
6.2.2. By Indications
6.2.3. By Drugs
6.2.4. By Distribution Channel
6.2.5. By Application
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Beta blockers Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Type
6.3.1.2.2. By Indications
6.3.1.2.3. By Drugs
6.3.1.2.4. By Distribution Channel
6.3.1.2.5. By Application
6.3.2. Canada Beta blockers Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Type
6.3.2.2.2. By Indications
6.3.2.2.3. By Drugs
6.3.2.2.4. By Distribution Channel
6.3.2.2.5. By Application
6.3.3. Mexico Beta blockers Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Type
6.3.3.2.2. By Indications
6.3.3.2.3. By Drugs
6.3.3.2.4. By Distribution Channel
6.3.3.2.5. By Application
7. Europe Beta blockers Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Type
7.2.2. By Indications
7.2.3. By Drugs
7.2.4. By Distribution Channel
7.2.5. By Application
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Beta blockers Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Type
7.3.1.2.2. By Indications
7.3.1.2.3. By Drugs
7.3.1.2.4. By Distribution Channel
7.3.1.2.5. By Application
7.3.2. France Beta blockers Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Type
7.3.2.2.2. By Indications
7.3.2.2.3. By Drugs
7.3.2.2.4. By Distribution Channel
7.3.2.2.5. By Application
7.3.3. United Kingdom Beta blockers Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Type
7.3.3.2.2. By Indications
7.3.3.2.3. By Drugs
7.3.3.2.4. By Distribution Channel
7.3.3.2.5. By Application
7.3.4. Italy Beta blockers Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Type
7.3.4.2.2. By Indications
7.3.4.2.3. By Drugs
7.3.4.2.4. By Distribution Channel
7.3.4.2.5. By Application
7.3.5. Spain Beta blockers Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Type
7.3.5.2.2. By Indications
7.3.5.2.3. By Drugs
7.3.5.2.4. By Distribution Channel
7.3.5.2.5. By Application
8. Asia Pacific Beta blockers Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Type
8.2.2. By Indications
8.2.3. By Drugs
8.2.4. By Distribution Channel
8.2.5. By Application
8.2.6. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Beta blockers Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Type
8.3.1.2.2. By Indications
8.3.1.2.3. By Drugs
8.3.1.2.4. By Distribution Channel
8.3.1.2.5. By Application
8.3.2. India Beta blockers Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Type
8.3.2.2.2. By Indications
8.3.2.2.3. By Drugs
8.3.2.2.4. By Distribution Channel
8.3.2.2.5. By Application
8.3.3. Japan Beta blockers Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Type
8.3.3.2.2. By Indications
8.3.3.2.3. By Drugs
8.3.3.2.4. By Distribution Channel
8.3.3.2.5. By Application
8.3.4. South Korea Beta blockers Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Type
8.3.4.2.2. By Indications
8.3.4.2.3. By Drugs
8.3.4.2.4. By Distribution Channel
8.3.4.2.5. By Application
8.3.5. Australia Beta blockers Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Type
8.3.5.2.2. By Indications
8.3.5.2.3. By Drugs
8.3.5.2.4. By Distribution Channel
8.3.5.2.5. By Application
9. Middle East & Africa Beta blockers Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Type
9.2.2. By Indications
9.2.3. By Drugs
9.2.4. By Distribution Channel
9.2.5. By Application
9.2.6. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Beta blockers Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Type
9.3.1.2.2. By Indications
9.3.1.2.3. By Drugs
9.3.1.2.4. By Distribution Channel
9.3.1.2.5. By Application
9.3.2. UAE Beta blockers Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Type
9.3.2.2.2. By Indications
9.3.2.2.3. By Drugs
9.3.2.2.4. By Distribution Channel
9.3.2.2.5. By Application
9.3.3. South Africa Beta blockers Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Type
9.3.3.2.2. By Indications
9.3.3.2.3. By Drugs
9.3.3.2.4. By Distribution Channel
9.3.3.2.5. By Application
10. South America Beta blockers Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Type
10.2.2. By Indications
10.2.3. By Drugs
10.2.4. By Distribution Channel
10.2.5. By Application
10.2.6. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Beta blockers Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Type
10.3.1.2.2. By Indications
10.3.1.2.3. By Drugs
10.3.1.2.4. By Distribution Channel
10.3.1.2.5. By Application
10.3.2. Colombia Beta blockers Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Type
10.3.2.2.2. By Indications
10.3.2.2.3. By Drugs
10.3.2.2.4. By Distribution Channel
10.3.2.2.5. By Application
10.3.3. Argentina Beta blockers Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Type
10.3.3.2.2. By Indications
10.3.3.2.3. By Drugs
10.3.3.2.4. By Distribution Channel
10.3.3.2.5. By Application
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Beta blockers Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Pfizer Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Novartis AG
15.3. Merck & Co. Inc
15.4. AstraZeneca PLC
15.5. Johnson and Johnson Services, Inc.
15.6. Eli Lilly and Company
15.7. Sanofi SA
15.8. Bristol-Myers Squibb
15.9. Bayer AG
15.10. GlaxoSmithKline plc
16. Strategic Recommendations
17. About Us & Disclaimer